Dupixent Lawsuit
Sanofi and Regeneron’s biologic drug Dupixent (dupilumab) has been linked in patient reports and emerging studies to serious eye conditions, inflammatory reactions, and other complications, raising concerns about inadequate warnings.
Last updated May 25, 2026
•ACTIVE CASES
TOP ESTIMATE
RISK DEVELOPING CTCL*
STATUTE WINDOW
OVERVIEW
Dupixent Lawsuit Overview
What is Dupixent?
Dupixent is a prescription biologic injection used to treat eczema, asthma, and chronic sinus conditions by targeting specific immune pathways. It has been widely prescribed across the U.S. since FDA approval in 2017.
The side effects concern
Recent studies and adverse event reports have linked Dupixent use to eye-related complications such as conjunctivitis, keratitis, and vision disturbances, along with immune-related reactions in some patients.
Manufacturer’s alleged liability
Lawsuits allege that Sanofi and Regeneron failed to adequately warn patients and healthcare providers about the severity and frequency of these risks, particularly long-term eye damage and inflammatory conditions.
Who is eligible?
Individuals who used Dupixent and later developed serious side effects, especially eye injuries, vision problems, or severe inflammatory reactions may qualify. A confirmed diagnosis after use is typically required.
The Complete Dupixent Lawsuit Guide
FREE PDF • 47 PAGES
The Complete Dupixent Lawsuit Lawsuit Guide
Everything you need to understand your legal options, written in plain English by legal and medical experts.
LITIGATION PROGRESS
Dupixent Lawsuit Timeline
April 2026
Manufacturers backed Dupixent MDL consolidation, but sought New York venue, not Georgia.
March 2026
Attorneys seek Georgia MDL for Dupixent lawsuits alleging CTCL in three victims.
February 2026
Projected $20B Dupixent sales fuel concerns profit motives outweigh growing safety lawsuits.
January 2026
Florida suit alleges Dupixent caused CTCL and makers knew the risk.
Estimated Payout
Case Severity Levels
Early Symptoms
Mild but persistent issues such as eye irritation, redness, dryness, or discomfort developed after starting Dupixent.
Progressive Conditions
Worsening complications, including chronic conjunctivitis, keratitis, or recurring inflammation requiring medical treatment.
Long-Term Impact
Serious or lasting conditions such as vision impairment, corneal damage, or complications affecting daily life and independence.
*Claim outcomes depend on diagnosis, timing, and medical records. Similar cases may be valued differently based on each person’s circumstances.
Find a lab nearby
Locate certified MRI and neurology imaging centers to obtain the diagnostic records needed to support your claim.
What to request : Ask for a contrast-enhanced brain MRI specifically looking for meningioma. Request both the radiologist's report and the imaging CD both are needed for your legal claim.
The process
How it works
From submission to attorney match, every case follows the same four-step review.
Submit your case
Answer a quick, secure questionnaire about your Dupixent use and symptoms.
Initial review
A specialist reviews your submission and checks eligibility.
Case manager call
You may be contacted to discuss medical history and records.
Attorney match
If eligible, your case may be referred to a lawyer handling similar claim.
References
SOURCES
Updated May 25, 2026
U.S. Food and Drug Administration
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/april-june-2025-potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event
National Institutes of Health
https://ncats.nih.gov/sites/default/files/2024-09/NCATS-Council-letter-September-2024-508.pdf
National Library of Medicine
https://pubmed.ncbi.nlm.nih.gov/40537179/
Judicial Panel on Multidistrict Litigation
Hearing Session Filed_ May 2026.pdf
Free Case Evaluation
Check your eligibility today.
Estimated Range